Silence TherapeuticsSTU:XRP2 46 Forward Dividend Yield % is 0.00% as of Jul. 03, 2026. GuruFocus rates STU:XRP2 with a GF Score™ of 46/100 and a GF Value™ of €0.31 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 149 Biotechnology companies, Silence Therapeutics ranks worse than 671140.27% on this metric.
As of today (2026-07-03), the Forward Annual Dividend Yield of Silence Therapeutics is 0.00%.
As of today (2026-07-03), the Trailing Annual Dividend Yield of Silence Therapeutics is 0.00%.
STU:XRP2's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.27 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Silence Therapeutics Forward Dividend Yield % Related Terms
STU:XRP2 vs IMRX, VRXA, MGNX: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Silence Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Silence Therapeutics (STU:XRP2) has a Forward Dividend Yield % of 0.00% as of Jul. 03, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Silence Therapeutics and its competitors. According to the industry distribution chart, Silence Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry.
Is Silence Therapeutics' Forward Dividend Yield % too high?
Silence Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Silence Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silence Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Forward Dividend Yield % compare to IMRX and VRXA?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Silence Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.27, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Silence Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Silence Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (STU:XRP2) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.31, compared to a current price of €9.20 — trading 2867.7% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Silence Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Silence Therapeutics (STU:XRP2), the current Forward Dividend Yield % is 0.00% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (STU:XRP2) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of €9.20 is trading 2867.7% above its estimated GF Value™ of €0.31.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:XRP2:
Forward Dividend Yield %: 0.00%
GF Value™: €0.31 vs. price of €9.20 (2867.7% above fair value)
No single metric tells the full story. See the STU:XRP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
46GF Score
Get the complete analysis for STU:XRP2
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XRP2 has been successfully added to your 